These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37924016)

  • 21. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
    Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
    Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
    Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.
    Tao Y; Zhou H; Niu T
    Front Pharmacol; 2021; 12():758992. PubMed ID: 34925019
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
    Wang J; Shang JJ; Jin S; Yao Y; Yan Z; Wu DP; Fu CC
    Zhonghua Nei Ke Za Zhi; 2022 Jan; 61(1):95-98. PubMed ID: 34979777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
    Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
    Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
    Badawi MA; Engelhardt B; Dobkowska E; Deng R; Kaufman JL; Menon R; Salem AH
    Invest New Drugs; 2024 Dec; 42(6):635-643. PubMed ID: 39388024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
    Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
    Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
    Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 32. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
    Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 37. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events.
    Bolaman AZ; Turgutkaya A; Sahip B; Selim C; Eroğlu Küçükerdiler H; Ertop Ş; Sargın G; Yavaşoğlu İ
    Turk J Haematol; 2021 Feb; 38(1):41-48. PubMed ID: 33342205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of venetoclax combined with demethylating agents in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Wei MY; Yin J; Liao Y; Liu JY; Zhao Y; Chen XM; Liu Y; Wang XM; Huang CL
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):1837-1846. PubMed ID: 38497866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
    Fu WJ; Wang YF; Zhao HG; Niu T; Fang BJ; Liao AJ; Bai H; Lu J
    BMC Cancer; 2022 Jul; 22(1):722. PubMed ID: 35778685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.